Neuspera Medical Secures $23M Series D Funding for Miniature Sacral Neuromodulation System to Treat Overactive Bladder

Jul 16, 2024 22:15 CST Updated 22:15

NeuSpera

Developer of Implantable Medical Devices

Neuspera MedicalAnnounced the completion of a new $23 million financing round, led by Vertex Ventures HC and Treo Ventures,Olympus Innovation Ventures、Action Potential Venture Capital, Windham Venture Partners, and others participated as co-investors. The funds raised in this round will be primarily used for its core productNeusperaPremarket Approval (PMA), applicable toTreatmentOveractive Bladder（OAB）。

Investor Evaluation

"As the preferred partner of urology innovators, we are delighted“We are pleased to invest in the NeuSpera Medical team, as they have secured FDA approval for NeuSpera and brought it to market. Driven by critical unmet market and patient needs, evolving societal guidelines, and positive feedback from patients and physicians in clinical trials, we are excited to support the NeuSpera Medical team as they develop innovative NeuSpera solutions for overactive bladder (OAB).”

---Gabriela Kaynor, President of Olympus Innovation Ventures and Chief Strategy Officer of Olympus Corporation

Executive Evaluation

“We are pleased to welcome new partners as we approach the next major milestone in submitting NeuSpera for regulatory approval.” Olympus Innovation Ventures“The confidence and conviction of both new and existing investors attest to the strength and potential of our platform’s technology.”

---Steffen Hovard, CEO of NeuSpera Medical

RootAccording to market statistics, as many as 37 million adults in the United States suffer from overactive bladder (OAB), of whom 4.5 million require neuromodulation therapy. Additionally, 19 million American patients suffer from fecal incontinence. Although overactive bladder (OAB) and fecal incontinence are not life-threatening, these conditions significantly impair patients’ quality of life and have substantial adverse effects on their mental health, sleep, work, and social activities.

Implantable Sacral Nerve StimulationThe device is a highly effective treatment for overactive bladder (OAB) and fecal incontinence. To this end, Boston Scientific planned to spend $3.7 billion at the beginning of the year.BeautyMedtronic attempted to acquire Axonics. However, the acquisition was never closed due to intellectual property issues between Axonics’ products and Medtronic. The fact that Medtronic went to great lengths to obstruct Boston Scientific’s acquisition of Axonics underscores the significant market size.

Therefore, an increasing number of companies are entering the large market for the treatment of overactive bladder (OAB).Neuspera MedicalDeveloped through technological innovation, the currently smallest implantable sacral nerve stimulator---Neuspera。NeusperaPromisingAddressing the numerous complications associated with traditional sacral nerve stimulation therapy (veryA large proportion of complications are due to traditionalSacrumdue to the large size of the neurostimulator).NeusperaBy reducing sacral nerve stimulationdevice volume, which not only reduces complications but also makes the entire surgical procedureDeSimple and reliable.

NeusperaInnovative technology has also attracted the attention of Olympus, another global urology giant. Although it is currently unclear whether Olympus will acquire the company in the future, securing financial and market support from Olympus will enableNeuspera MedicalBecome more competitive.

Neuspera

NeusperaIt is the first ultra-miniaturizedPeripheral NerveStimulator(PNS), which is smaller than the smallest commercially availableThe pulse generator is 75 times smaller, and compared to currently available technologies, it offersThe physician provides opportunities for more in-depth anatomical targeting.

NeusperaComposed of micro-implantable electrodes, a wearable wireless generator, and an app.

Micro-implantable electrode

The micro-implantable electrode has a diameter of only 2 mm and a volume of just 0.03 mL. Its modular structure allows it to adapt to various neural interfaces.Micro-implantable electrodesIt features a range of programmable stimulation parameters, including frequency, pulse width, and amplitude (voltage) for current control, thereby offering significant flexibility in addressing common neuromodulation applications.

NeusperaUtilizing proprietary Mid Field Powering technology, enabling wearable wireless generators to powerLong-Distance Miniature Implantable ElectrodesCharging, Depth of ChargeAchievable10cmThe above.

Meanwhile, the micro-implantable electrode employs a proprietary sealing technology, thereby reducing its size to only that of traditionalThe neuromodulator is one percent the size, making the entire implantation process simple and controllable, thereby reducing postoperative pain and complications for patients.

Wearable Wireless Generator

The wearable wireless generator is compact and lightweight, capable of being deeply implanted within the body.Wireless Charging of Micro-Implantable Electrodes. In addition to wireless charging, the transmitter also features automatic detection (of micro-implant electrodes and human tissue), automatic power steering, and automatic data collection.

APP

Patients can access NeuSperaPackaged inOn MobileNeuspera APP, adjust their treatment parameters, modulate stimulation status, and perform other functions.

NeuSpera Demo

Neuspera Medical

Neuspera MedicalNeuSpera Medical, Inc. is an innovative medical device company dedicated to developing implantable medical devices to improve the lives of patients battling chronic diseases. The NeuSpera platform aims to provide patients and physicians with new therapeutic options that are potentially earlier-intervention, less invasive, and more adaptable. These therapies are designed to help patients restore their health and well-being, thereby enhancing their quality of life.